Mediwatch is a small company destined to become a much bigger fish by the time this year is out. Mediwatch are already a market leader in urological medical diagnostics equipement and are currently exporting their products throughout the UK, Canada, Europe, India and Japan. That doesn't leave much of the globe left for them to capture - until you remember the good ol' US and China. These are the two massive markets which are destined to be added to MDW's export client portfolio by the end of 2005.

Website: www.mediwatch.com

The company is currently heavily undervalued. This is probably because Mediwatch's speciality is not a very glamourous business to be in as their equipment is used extensively to diagnose prostate cancer in men and other nasty urological conditions affecting both men and women. However, don't let that put you off investing in these guys. This is big business and is growing at an exponential rate as more and more people globally become health-aware as they get older. Mediwatch normally supply their products through to global markets via distribution agreements. They already have the best of distribution partners in the well known US medical distributor CR Bard who supply Canada and Europe and GE Medical who supply Japan. The UK business is handled by Mediwatch's own dedicated sales team. US FDA approval was gained for MDW's products at the start of last year, however a whole year of US legal wrangling meant that they were unable to seek a suitable partner for the crucial distribution agreement until the start of this year. This distribution agreement is expected by the board to have a "significant effect" on the share price so they are reluctant to give any clues as to when it will be signed, sealed and delivered. The general consensus is that this US distribution agreement will be announced in July/August. In China and Hong Kong, MDW have done things the other way round. They have set up distribution agreements with major Asian medical equipment distributors and have stock already out there waiting to sell into the markets - all they are waiting for is SDA approval (which is a "rubber stamp") from the Chinese authorities - this can take anything up to 12 months to come through and MDW applied during Autumn 2004 - so even more good news coming soon this year. Epidemiological data from British Association of Urology conference last year: On average 30-45% of all men between the age of 50 and 70 have at least one PSA test per year in the US / Italy / Australia. If that's not enough to convince you to invest a few hard earned coppers in MDW, they are also developing a PSA stick test product (PSAWatch) which is revolutionary and causing some excitement in medical circles. This product can also be adapted (at very low cost) for a whole spectrum of medical disciplines from Cardiology to Veterinary Practice! This product is likely to be released in the next few weeks. Philip Stimpson the CEO has said that this product is going to be their "gold mine" - I'm sure it will prove to be ours too.

Treble,
Was PSAwatch taken into account within the research note and the possible revenue that would be generated?
Rightly or wrongly MDW have always been about their PSAwatch system but there is much more to this company now.
Further distribution deals are more likely than not as they become more settled in their new areas-imo.

Good luck anyway.

PS CS. was where the bulk of my money has been over 5 years + so I can sit happy with my holdings in MDW for as long as it takes and yes I do get emotional about them sometimes-lol

If any company was due a re-rating this one is!
MDW will be getting CE approval for PSAwatch this month and FDA approval in the summer of 2007.
At the present time it roughly costs the health service 50 for a PSA test as the person has to go to his GP to get a blood sample and then the sample is sent to a lab which takes about a week for the result,causing lots of stress for those awaiting the results along with family members.

The PSAwatch sysem is a 10 minute accurate test of a persons PSA level at a cost to the GP of about 6,the test can be carried out in the GP's surgery.Prostate cancer is a very big killer in the UK and the rest of the world and this test will reduce the deaths caused by this disease from the early detection,as simple as that.
IMO,the plan would be to offer the test to anyone over 40 and build up a chart and any rises would then result in a further PSA test along with a DRE which would then lead to further investigation if required.
The point is this new test will give the GP a chance to monitor all of his male patients for PSA levels at very little cost with a view of catching this very common and if found early treatable disease!

There ends the lecture........


Edit-I probably shouldn't keep on going about this but......My father had his prostate gland taken out,rightly or wrongly about 6 years ago,never been tested before that and after all the options,which were not that much bit the bullet and took his choice.Last Friday he got the results (from his three monthly check) of the week before test and it's thankfully around his normal of 0.7 which is very good for his age.

On a darker side the bloke over the road who complained of back pain in December 2006 who never had a PSA test in his life (like most)on further testing had a PSA result of 600-700 and has three years to live!

The PSA test on it's own does not save lives but can lead a GP to forward a patient if PSA readings are on an upward trend for further investigation.Once PSAwatch becomes common in the GP's surgery it must be obvious that more Men will be tested and more lives will be saved!!

CE Approval confirmed ... next step in the road to success for this brilliant littlew company.

mg;-)
OH happy days

Where's treble :) ???

mg still here old bean........not overly worried by the massive 3% rise today :-)...if this is the best they can do chart looks like lower high and back down we go....remember p/e of 100 for 2007 :-))

lol Treble

Trebs... hate to disagree with you but I see the pattern as a bullish pennant/triangle thingy:-)

me julie...i see it as a bearish wedge :-) but you Ozzies are always upside down :-) my short is only small and only really for a bit of sport and carry on with some folks so kind of hope it all goes well fur ye

Treb.... always knew I was upside down:-0)

Ah, that's better - had an 'orrible thought that he might have closed his short :)

Not to put too finer point on it - but his DVS punt obviously showed how accurate treb's forecasts are - always worth going the opposite way :)))

again thansk for reminding me of that mg old bean

Always happy to oblige young thing ;-9

This company Rocks.

This was on the Elemental website before but worth another read now we have CE approvals for PSAwatch:

"With the increasing pressure on the NHS to move diagnostic services away from the acute settings, PCTs are having look for innovative solutions to fulfil these services at the point of care.

Diagnostic urology and uro-gynaecology have been identified by the NHS as a priority service to move to the point of care setting. Until now the level and complexity of the diagnostic tools has been expensive in both cost and skill base requirements.

Today, Elemental Healthcare Ltd, can now offer the UKs most effective one stop solution for diagnostic urology through the Mediwatch urological assessment system.

Key to the system is the Multiscan which offers real time imaging of the bladder, kidney and prostate. Portable, easy to use the Multiscan will manage data from all the other components of the system via blue tooth technology thereby enabling complete assessment reports at your figure tips.

PSAwatch provides a fast effective solution for the management of of new & recurrent prostate disease with accuracy of 98% (Check Figure). Ease of use combined with state of the art assessment analysis allows the user clear result with 10 minutes. Linked to the Multiscan by blue tooth the PSA result an be used with the the measured prostate volume to calculate the PSA density.

Uroflow Systems offers an integrated solution for the assessment of urinary flow and is easily adapted for both male and female patients. The assessment result can be reviewed separately or as a combined assessment report via the Multiscan system."

Just in case anyone missed this :-)



Mediwatch PLC
21 February 2007


Issued by Citigate Dewe Rogerson Limited, Birmingham
Date: Wednesday 21st February 2007
Embargoed: 7.00am
Mediwatch plc
('Mediwatch' or 'the Company')
Mediwatch receives PSAwatch CE approval

Further to the Company's announcement on 11th December 2006, the Directors of
Mediwatch (AIM: MDW), the high-tech medical diagnostic equipment manufacturer
and supplier are pleased to announce that the Company has received CE approval
for PSAwatchTM, its quantitative point-of-care diagnostic test for prostate
disease.

Mediwatch's new PSAwatchTM test and the portable Bioscan reader system (with an
A5 footprint) will be one of the first low-cost, quantitative, portable,
point-of-care PSA (prostate-specific antigen) assay systems.
PSA is a blood test used routinely for diagnosis and surveillance of diseases of
the prostate, which are some of the most common problems encountered by
clinicians in adult urological practice. Approximately 40 million PSA tests are
done worldwide, annually. PSAwatchTM measures PSA from a finger-prick sample of
blood, in just 10 minutes. Previously, men would often wait days or even weeks
for results as a blood sample, was sent to a hospital laboratory.

Commenting on the CE approval, Philip Stimpson, Chief Executive, Mediwatch said:

'This is an exceptional achievement for Mediwatch. We believe we are the only
Company with a completely integrated diagnostic platform for prostate disease.
PSAwatchTM is the last piece of the jigsaw which completes our One-Stop
Diagnostic System.

'We pride ourselves in our systematic and innovative approach to diagnostic
solutions. PSAwatchTM is inexpensive and ideal for use in outreach clinics, GPs,
outpatient departments and urology clinics and provides a true One-Stop
service.'

Mediwatch intends to launch PSAwatchTM and the Bioscan reader system at the
forthcoming European Association of Urologists ('EAU') Meeting in Berlin on 21
-24 March 2007 with sales of the PSAwatchTM system into the European market
expected to commence in the second calendar quarter of 2007. The US FDA approval
is being targeted for Summer 2007 and, subject to the same, the Directors
anticipate that marketing in the US will commence in the Autumn 2007.

Enquires:
Mediwatch plc Citigate Dewe Rogerson
Philip Stimpson, Chief Executive Fiona Tooley, Director
Kevin Middis, Finance Director Katie Dale, Senior Account Manager
Tel: +44 (0) 1788 547888 Tel: +44 (0) 121 455 8370

www.mediwatch.com

Ticker: AIM : MDW

Canaccord Adams Limited
Robin Birchall
Tel: +44 (0) 20 7050 6500

Editors Note:
Mediwatch plc:
Founded in 1995, Mediwatch has developed a range of medical equipment for the
diagnosis of urological disorders. The business focuses its design skills
towards diagnostic products that can be used across the medical profession. With
the acquisition of the Medtronic Urodynamics business, completed in December
2006, Mediwatch added a number of complementary and well established capital
equipment and disposable products to Mediwatch's existing range. PSAwatchTM
enhances this range of disposable products.

Urology Diagnostics:
Urology is the study and treatment of diseases of the urogenital tract.
Awareness of urological disorders and patient-specific disease management is
increasing with on-going advances in the quality and specificity of diagnostic
testing. Mediwatch is striving to develop and market faster, simpler, and less
invasive diagnostic products to save lives and restore quality of life for
people with urological conditions.

From the other side:

"Recent developments in PSA testing
Mr Omer Karim, MB BS, MS, FRCS (Urol)
Consultant Urological surgeon, The Princess Grace Hospital,
Heatherwood and Wrexham Park Hospital and St Mary's Hospital, Paddington

Diagnosing prostate cancer remains a clinical challenge. A digital rectal examination is around 40% sensitive to identifying issues. PSA testing is around 60% sensitive.

But PSA testing itself requires more than one consultation and the time delay between the test and outcome of laboratory work leaves patients in a state of anxiety between appointments.

A new development in PSA testing - PSA Watch - works in the same way as blood glucose testing.

A specially developed strip from Mediwatch Biomedical Ltd provides in-clinic results of PSA levels for a patient within 10 minutes and without the need for laboratory testing.

By placing a small amount of blood on the strip, a PSA read out is available, shown against a 'norm' and accurate for readings as low as 0.25. A second antibody read out on the same strip is in development.

Unlike many new developments, there is a cost advantage too. Each strip costs 5 compared to an average laboratory cost of 12.

The key patient benefit of PSA Watch is the immediate PSA level result and the ability to provide advice for any appropriate action on the spot, reducing anxiety of waiting for test outcomes.

The key clinical efficiency benefit is removing the need for a re-visit to determine and advise the patient whether PSA levels indicate active monitoring, further diagnosis or specific treatment. It can all be accomplished at a single consultation."



http://urologycentrelondon.co.uk/news_psadevelopments.html

MDW looking good for future growth-imo

The NHS are trying to save money (obviously) left right and centre.

The London Urology Centre is a new website.

The new Elemental website is targeted for the UK market for both NHS and the Private Practice.

They are both heavily linked to Mediwatch.

Mediwatch has the cream of Medtronic's Urology suit.

Mediwatch have their own equipment that compliments the newly acquired Medtronic equipment to form a complete package for any Practice to set up a reasonably cheap Urology department to carry out accurate tests once only available to expensive systems found in Hospitals and now with the technology to send data directly to a major Hospital for further analysis or record keeping.


Well,I have dug me hole now-lol


From small General Practices which may only require the basic systems to relay the information to a city centre Private Practice which would have the full range of MDW products which in turn would either carry out further investigations or pass on to a NHS Hospital with a leaner workforce (due to preliminary tests being carried out at the GP level)to further the tests or combine with the Private Practices to increase patient through put............

Just some thoughts after looking at the way a small UK company has acquired a major USA/World companies Urology department ie Medtronic and with the strong links both companies have had with the NHS and with cost cutting excercises which are made achievable as modern,accurate and cheaper products come to the market place!
Along with two recent companies wanting to be involved with MDW and are.


Hope this doesn't sound like a ramp as it's not meant to be and if floored the day crew will soon put me right-lol

Good Evening and what a splendiferous,if not pretty,win by the Boro tonight!

Just typing outloud here relating to a Department of Health working group report from 13th JANUARY 2004 (I have looked at it quite often since it's arrival on the web,many months ago) and with Newsnight tonight and the ever changing NHS(only a very small part in deciding to write this tonight)

First of all our CEO Philip Stimpson,although not present at the particular meeting I am quoting from but non the less was heavily involved in these meetings over the time.

So,I will be quoting what I think are key points from the minutes which I believe were part of MDW's plan with or without assistance :

AGENDA ITEM 3: MATTERS ARISING

3. Progress reports on the last meetings "action points" were taken:

PRIORITIES
Bob Bish circulated statistical information on UK healthcare device exports to the EU, certain Accession States, the USA, China, India and Japan (Annex1).

HUB AND SPOKE HEALTHCARE NETWORKS
At the first meeting the Group noted the "hub and spoke activities" of American Healthcare Groups in overseas markets. They wondered whether the NHS could become a competitor. Stuart Smalley stated that he believed that the NHS would not develop satellite facilities overseas in the foreseeable future.


RESOURCES FROM OFFICIAL SOURCES
Bob Bish reported that UKT&I spend on supporting healthcare exporters amounted to 1.2m. The largest element was 644k for support for exhibitions and seminars overseas. The total figure did not included departmental running costs such as pay. David Crossman expressed concern that these figures did not represent an accurate total spend. Bob Bish acknowledged that the figures were central figures and did not include RDA/regional and other government expenditure on trade.

AGENDA ITEM 4: OVER ARCHING ASSUMPTIONS

4. Following a short discussion it was agreed that it was essential to have an agreed base of assumptions from which a work programme could flow. A draft of over arching assumptions was tabled (Annex3) and comments invited. The draft was approved and Assumption 4 "global success is contingent upon success in the USA" strongly endorsed by Arthur Kay and David Crossman. In their view even inexperienced exporters could not afford to ignore 50% of world demand for healthcare products. Market dynamics would quickly indicate whether a product was competitive; something that happened more slowly in other territories. Moreover FDA approval was a key selling point outside the USA.
******I put the stars in for the above line and "global success is contingent upon success in the USA" strongly endorsed by Arthur Kay and David Crossman******


It was considered that UKTI support for companies exporting or wishing to export to the USA should be based upon support to attend appropriate major US conferences / exhibitions. Attendance at general purpose medical exhibitions in the USA is considered of marginal benefit. This support should be based on individual company specific needs.

****Me again,the above shows the path MDW followed/follows and along with combining with a major USA company at such events ie Medtronic and with MDW then taking over their Urology section (all with FDA approvals which ties in with the 'stars' above this one....***********************8

. Discussion focused on Assumption 5 "China likely to become the leading market in the world" and this was endorsed. The meeting were advised of the joint work between UKTI and DHI and the real market opportunities which had been identified in Shanghai. It was agreed that WG4 should recommend that both China and the USA be regarded as key markets and programmes to exploit the potential developed accordingly.
******Only me,well we have the USA tied up and already have outlets to China which I'm sure will be improved somewhat with our new hold on this sector******



HITF WG 4 Suggested Work Themes
***There are a few sections to this but rather than listing them they will be covered in my conclusion(the link to the whole document is at bottom of page)*********

AGENDA ITEM 6: ANY OTHER BUSINESS

TEAMS OF EXPERTISE

7. Peter Simpson (not to be confused with Stimpson,as I often do) strongly recommended the creation of multi disciplinary teams containing different levels of expertise. The teams would focus on one aspect of healthcare PFI, diabetes and so on. The expertise could then be drawn down on a properly managed basis rather than on an ad hoc basis that typified current activity. It would also ensure that the appropriate level of expertise was deployed on each occasion.


Conclusion:

1. Both MDW and MDT have been key players in our NHS

2. The points put forward have been those that have been achieved by Mediwatch (MDW),starting from about the time of this meeting took place!

3. MDW have setup an existing supplier to the NHS ie Elemental Healthcare Ltd to distribute their products/systems to the UK market,that is both the Private sector and the NHS
http://www.elemental-healthcare.co.uk/

4. "Stuart Smalley stated that he believed that the NHS would not develop satellite facilities overseas in the foreseeable future."

Well,MDW went one better and produced a satellite facility which by all accounts is up and running in Florida USA,which could become the main 'Hub' for the world.

My point is that the NHS formed a group in early 2000 to find a profit margin abroad but from the way I see it,as in most massive companies they were too slow.MDW saw the market and with a base product in Urology ie PSAwatch started on the long road (as far as share holders were concerned)in building up a 'one stop Urology Shop' where all their systems talk to each other via normal networking or the latest Bluetooth.This enables all the various Urology tests to be sent to a central data base ie From the GP to a central function ie Hospital.


The above is just my view from the doc.link below that has plagued on me mind for a few years-lol.

I am not saying buy these shares but any opinion on the above would be most welcome.


http://www.advisorybodies.doh.gov.uk/hitf/wg4meeting2.htm

The AGM is tomoorrow and unfortunately I won't be able to go. I have already spoken to Kevin Middas and they seem to be well on top of everything (even if we have thought they aren't).The product is to be launched at the end of March at the EAU. This is the biggest urology meeting outside the USA... attended by 12,000 urologists.
I also spoke to the PR company.. and am impressed, so that bodes well for the future presentations needed.
The importance of getting the PSA watch into the markets to detect this ferral disease is only too important and for those who don't read teh competitors MDW board, this post by Reg sums it up (reproduced with his permission)




BoringREG - 26 Feb'07 - 11:55 - 9 of 13


Most blokes


Prostate problems. Equally, most think that Prostate problems are what old blokes get.

Back in the summer of 2004 I certainly had these opinions. In fact, when I went to my GP with what was proving to be a problem my GP - a bloke of around my age - needed to be persuaded to send off a blood sample. In fact he suggested I was too young to worry about Prostate cancer and doubted that a PSA test was needed.

I was 53.

Within a couple of weeks I received a letter from my GP telling me that my PSA levels were higher than normal and I would need to go to a urologist to have an internal examination which would also include a biopsy.

My PSA level was 19 - normal would have been below 4.

Unfortunately the examination proved positive and a further PSA test showed it had risen to 24. Also, unfortunately, the cancer had broken out of the gland and, therefore, surgery was not an option.

Had I gone for a screening before I did - persuading my GP to do it and send it off - the options would have been increased.

As it is, the cancer is inoperable and I need to have medication to control its growth.

One of the associated problems of Prostate cancer is that it usually spreads to your bones. This has happened to me as well so, as well as regular MRI/CT scans I have also had 3 bone scans to assess the level of development of prostate cancer on my bones.

I am now 55 and the cancer is being "managed" using hormone treatments which, unfortunately, have a limited impact and, eventually, the cancer will become hormone resistant.

My oncologist has changed the medication a few times and, although the initial treatment proved to have an immediate effect that is no longer the case. Equally, the alternative initially had an impact but that too is no longer having the same impact.

How do they measure how I'm getting on, what interventions to take - regular blood tests to check my PSA level.

Going to the Cancer centre a week before seeing the consultant means that I always have that dreaded wait until I know whether the drugs are doing OK or not.

All in all, for me and thousands of other blokes in their middle and older ages, the arrival of the PSAWatch and MDW's other products are critical:

a) More frequent, simple, screening which would lead to early intervention
b) Simple monitoring for those unfortunate enough to present too late
c) Simple monitoring for those who have surgical/radiotherapy treatment.

I have a lot of money invested in MDW for both personal and financial reasons.

PSAWatch will revolutionise the way Prostate (and other cancers) can be detected through mass screening at a Primary and Acute Points of Care. The "market" is huge and, being one of the potential beneficiaries I believe it will be massive.

There are plenty of blokes out there whose lives - and life expectancy will be transformed by this company's innovative products.

It's just that they don't want to see it or think about it - YET.

Hopefully, this little tale will inspire blokes out there to go and get tested. Very soon it will be a very simple task - because of PSAWatch.

The other thing you all need to do is make sure your GP is prepared to test you. Mine has been persuaded to do it more frequently and has, because of my experience now actually tested himself. Many practices, he assures me, are reluctant to test - because of their belief that it can lead to positive negatives i.e. false alarms.

Which is better, one wonders, a short period of uncertainty and the relief that comes from a false alarm or leaving the problem until it is too late for effective surgical intervention. I know what I would have preferred - although it would have put me in the hands/knives of the Willydoctors. If only !!

I'm not that worried whether it also inspires you to invest in the company. I know it will be a massive success. Whether I get to benefit financially may be another issue - but my wife and kids will :)

Boring Old REG

Let's hope that this is out there in the surgeries quicker rather than later , ... I have a feeling it will.
Jules